Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04675294 · ClinicalTrials.gov registry record · Phase 2

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by ALX Oncology.

Active
Registry status
Phase 2
Development phase
189
Enrollment target
20
Study locations

NCT04675294: Active Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by ALX Oncology.

NCT04675294 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by ALX Oncology. The registered enrollment target is 189 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04675294, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by ALX Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
189 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Conditions Studied

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG pembrolizumab
  • DRUG evorpacept

Study Locations (20)

California

  • Hoag Hospital - Irvine
  • University of California San Diego - La Jolla

Illinois

  • Rush University Medical Center - Chicago
  • Blessing Cancer Center - Quincy

Other

  • Ashford Cancer Centre Research - Windsor Gardens
  • Cliniques Universitaires Saint-Luc - Brussels

Florida

  • H. Lee Moffitt Cancer Center - Tampa

Georgia

  • Northwest Georgia Oncology Centers - Marietta

Maryland

  • University of Maryland Medical System - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

New Jersey

  • Rutgers Cancer Institute of New Jersey - Newark

Trial Details

FieldValue
Enrollment Target 189 participants
Start Date 2021-04-02
Est. Completion 2026-06-30
Phase Phase 2
ALX Oncology

9 total trials

What the registry record for NCT04675294 still lists

NCT04675294 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (27% lower).

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.

NCT04675294 names 20 study sites across 17 states, led by California, Illinois, Other.

Frequently Asked Questions

What is clinical trial NCT04675294 about?

NCT04675294 is a clinical study titled "Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)". A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

What is the current status of trial NCT04675294?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2021-04-02. Estimated completion is 2026-06-30.

What conditions does trial NCT04675294 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT04675294?

The interventions under investigation include: pembrolizumab (DRUG), evorpacept (DRUG).

Who is sponsoring clinical trial NCT04675294?

This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04675294 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04675294's enrollment target sits among peer trials

189 50th of 250 higher than 201 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02734537 · 189 participants · Phase 2

    Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • NCT05058651 · 189 participants · Phase 2

    Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

  • NCT05673408 · 189 participants

    NIBP Validation Study

  • NCT05994209 · 189 participants · Phase 1

    Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04675294, the US trial registry maintained by the National Library of Medicine. NCT04675294 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.